A large-animal model was developed to facilitate the noninvasive investigation of the effect on the human
glioma-derived D-54 MG (
glioblastoma multiforme) continuous cell line of a variety of therapeutic regimens. Twenty random-bred male cats were inoculated intracerebrally with 1 x 10(7) D-54 MG
tumor cells after being initiated on one of three preparatory regimens of
cyclosporin A p.o. Reproducible success of D-54 MG
xenotransplantation (100%, 6 of 6 cats) was achieved only after pretreatment with 120 mg
cyclosporin A p.o. (24-30 mg/kg) daily for greater than or equal to 10 days prior to
tumor implantation. High-performance liquid chromatography-derived whole blood
cyclosporin A 12-h trough levels of greater than or equal to 640 ng/ml were seen in successful implants. Lesions ranging from 2 to 20 mm in diameter were seen in cats sacrificed 27-44 days after implantation with no growth seen in control animals. Histopathological examination revealed the
tumors to be well-circumscribed anaplastic intracerebral
tumors with some invasion into surrounding host parenchyma. Perivascular lymphocytic cuffing was observed, but intratumoral lymphocytic infiltration was minimal.
Gadolinium-EDTA-enhanced nuclear magnetic resonance imaging provided accurate
tumor localization in T1-weighted images (TE 26 ms; TR 600 ms). Biochemical tests of kidney, liver, and hematological function were within normal limits, although 10% (2 of 20) of the animals developed
gingival hyperplasia, and 5% (1 of 20) developed
intussusception. The reproducible growth of the D-54 MG human
glioblastoma cell line in a large-animal model eliminates many of the limitations associated with the standard nude mouse/rat model, thereby providing a novel test bed for a variety of imaging modalities as well as for
drug immunoconjugate localization and toxicity studies.